Santander X Global Challenge | Reimagine Silver Age · 2025
Banco Santander with Philips and Oxentia Foundation
Medical neurotechnology
Deep-sleep neurostimulation in early Alzheimer’s disease
Elevvo is a patented closed-loop auditory stimulation device intended to modulate slow-wave activity during sleep in patients with early-stage Alzheimer’s disease.
- Deep-sleep stimulation
- Overnight use at home
- Remote clinical supervision
Device under clinical investigation
Clinical programme
Five clinical studies since 2022
5clinical trials
307participants/patients
4,084nights of treatment
31,700+hours of treatment
202220232024202520262027
Phase 1 · HOGARNCT06993207
Phase 1 · Nana-1CEICA PI23/382
Phase 1 · Nana-2CEICA PI24/076
Phase 2a · Nana-LabNCT07402590
Phase 2a · Nana-HomeNCT07672977
In collaboration with
Phase 2a · Nana-Lab
Efficacy in improving declarative memory in early Alzheimer’s disease
Randomised, cross-over, double-blind, placebo-controlled trial in 37 patients with early-stage Alzheimer’s disease and an amnestic phenotype. Elevvo significantly increased slow-wave amplitude and was associated with improved declarative memory versus placebo.
Declarative memory
More word pairs remembered after the night
Mean word-pair retention. Significant difference versus placebo, p = 0.04.
Mechanism
Larger slow waves during stimulation
Median slow-wave amplitude on the stimulation night versus the placebo night. Significant difference versus placebo, p < 10⁻⁶.
Full results of the Nana-Lab trial
Read the preprint on medRxiv →Regulatory noticeElevvo is an investigational device. Its safety and effectiveness are being established. Limited to investigational use.
Recognition
Innovation awards
IDEA Competition · IDEA Futuro category · 2026
Fundación Aragón Emprende, Government of Aragón
Professional contact
Let’s talk
For investors and clinical research centres.
Patient contact
Take part in our studies
Write to us and we will get in touch when we have new clinical trials.